VTGN (Vistagen Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by VTGN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | Douglas J Williamson | Director | A | — | — |
| 2026-07-02 | Nick B. Tressler | Chief Financial Officer | A | — | — |
| 2026-07-02 | Shawn Singh | President and CEO | A | — | — |
| 2026-07-02 | Reid G. Adler | Chief Legal Officer | A | — | — |
| 2026-05-19 | Angel S Angelov | Chief Medical Officer | A | — | — |
| 2026-04-09 | Elissa S. Cote | Chief Corp Development Officer | A | — | — |
| 2026-04-09 | Nick B. Tressler | Chief Financial Officer | A | — | — |
| 2026-04-09 | Reid G. Adler | Chief Legal Officer | A | — | — |
| 2026-04-09 | Joshua S. Prince | Chief Operating Officer | A | — | — |
| 2026-04-09 | Shawn Singh | President and CEO | A | — | — |
| 2026-01-05 | Joshua S. Prince | Chief Operating Officer | A | — | — |
| 2025-12-04 | Nick B. Tressler | Chief Financial Officer | A | — | — |
| 2025-11-04 | Paul R Edick | Director | A | — | — |
| 2025-09-11 | Mary L. Rotunno | Director | A | — | — |
| 2025-09-11 | JON S SAXE | Director | A | — | — |
| 2025-09-11 | Ann Michelle Cunningham | Director | A | — | — |
| 2025-09-11 | Margaret M FitzPatrick | Director | A | — | — |
| 2025-09-11 | Joanne Curley | Director | A | — | — |
| 2025-07-01 | Cynthia Lynn Anderson | CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-07-01 | Shawn Singh | President and CEO | A | — | — |
| 2025-07-01 | Reid G. Adler | Chief Legal Officer | A | — | — |
| 2025-07-01 | Joshua S. Prince | Chief Operating Officer | A | — | — |
| 2025-06-25 | Shawn Singh | President and CEO | A | — | — |
| 2025-06-25 | Reid G. Adler | Chief Legal Officer | A | — | — |
| 2025-06-25 | Cynthia Lynn Anderson | CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-06-25 | Joshua S. Prince | Chief Operating Officer | A | — | — |
| 2025-06-25 | Elissa S. Cote | Chief Corp Development Officer | A | — | — |
| 2025-01-13 | Cynthia Lynn Anderson | CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-01-13 | Joshua S. Prince | Chief Operating Officer | A | — | — |
| 2024-09-10 | Margaret M FitzPatrick | Director | A | — | — |
| 2024-09-10 | JON S SAXE | Director | A | — | — |
| 2024-09-10 | Ann Michelle Cunningham | Director | A | — | — |
| 2024-09-10 | JERRY B GIN | Director | A | — | — |
| 2024-09-10 | Joanne Curley | Director | A | — | — |
| 2024-09-10 | Mary L. Rotunno | Director | A | — | — |
| 2024-07-02 | Joshua S. Prince | Chief Operating Officer | A | — | — |
| 2024-07-02 | Cynthia Lynn Anderson | CHIEF FINANCIAL OFFICER | A | — | — |
| 2024-07-02 | Shawn Singh | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2024-07-02 | Reid G. Adler | CHF CORP DEVEL OFF, GEN COUNS | A | — | — |
| 2024-06-26 | Reid G. Adler | CHF CORP DEVEL OFF, GEN COUNS | A | — | — |
| 2024-06-26 | Shawn Singh | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2024-06-26 | Cynthia Lynn Anderson | CHIEF FINANCIAL OFFICER | A | — | — |
| 2024-06-26 | Joshua S. Prince | Chief Operating Officer | A | — | — |
| 2024-03-06 | JON S SAXE | Director | A | — | — |
| 2024-03-06 | Margaret M FitzPatrick | Director | A | — | — |
| 2024-03-06 | Mary L. Rotunno | Director | A | — | — |
| 2024-03-06 | Joanne Curley | Director | A | — | — |
| 2024-03-06 | JERRY B GIN | Director | A | — | — |
| 2024-03-06 | Ann Michelle Cunningham | Director | A | — | — |
| 2024-01-03 | Reid G. Adler | CHF CORP DEVEL OFF, GEN COUNS | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,575,000 | — |
| — | 10%+ Owner | 687,910 | — |
| — | President and CEO | 75,721 | — |
| — | Chief Legal Officer | 60,868 | — |
| — | Chief Operating Officer | 15,249 | — |
| — | CHIEF FINANCIAL OFFICER | 12,801 | — |
| — | Chief Financial Officer | 11,712 | — |
| — | Director | 6,666 | — |
| — | VP, CFO | 3,671 | — |
| — | PRES./CHIEF SCIENTIFIC OFFICER | 3,295 | — |
| — | Director | 1,859 | — |
| — | CHIEF MEDICAL OFFICER | 664 | — |
| — | Director | 83 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VTGN quote page; the site-wide leaderboard is on the insider transactions hub.